Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: Results from a retrospective claims database analysis

Journal of Medical Economics

Volumn 15, Issue 6, 2012, Pages 1039-1050

  Pelletier, Elise M ^a   Pawaskar, Manjiri ^b   Smith, Paula J ^a   Best, Jennie H ^c   Chapman, Richard H ^a  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Administrative claims; Database analysis; Exenatide; Liraglutide; Medical costs; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; EXENDIN 4; INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; SULFONYLUREA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT COMPLIANCE; PHARMACY; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEES, PHARMACEUTICAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PEPTIDES; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES; VENOMS; YOUNG ADULT;

EID: 84869756430     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.688903     Document Type: Article

References (13)

1. World Health Organization (WHO). Global Strategy on Diet, Physical Activity and Health. Diabetes Facts. http://www.who.int/hpr/gs.fs.diabetes. shtml. Accessed February 16, 2012 (Copyright 2003)
2. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. http:// www.cdc.gov/diabetes/ pubs/pdf/ndfs-2011.pdf. Accessed February 16, 2012
3. American Diabetes Association (ADA). Diabetes Basics: Prevention, Risk Factors. http://www.diabetes.org/diabetes-basics/prevention/risk-factors/. Accessed February 16, 2012 (Copyright 1995-2012)
4. Dall TM, Zhang Y, Chen YJ, et al. The economic burden of diabetes. Health Aff 2010;29:297-303
5. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
6. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005;4:361-70
7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
8. Pawaskar M, Zagar A, Sugihara T, et al. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. J Med Econ 2011;14:16-27
9. Misurski D, Lage MJ, Fabunmi R, et al. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Appl Health Econ Health Policy 2009;7:245-54
10. Lage MJ, Fabunmi R, Boye KS, et al. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Adv Ther 2009;26:217-29
11. Health Insurance Portability and Accountability Act (HIPAA), Pub. L. No. 104- 191,110 Stat.1936 2006. Washington, DC, USA: US Department of Health and Human Services
12. Lee WC, Conner C, Hammer M. Results of a model analysis of the costeffectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther 2010;32:1756-67
13. Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619-25